Correction to Merck-Cubist Deal Story
December 08 2014 - 6:49PM
Dow Jones News
Cubist Pharmaceuticals Inc. (CBST) projects global annual
revenue of $2 billion by 2017. "Merck to Buy Cubist Pharmaceuticals
for $8.4 Billion--2nd Update" at 7:59 a.m. EST incorrectly said
Cubist expects its flagship drug, Cubicin, to post annual revenue
of $2 billion by 2017.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024